To assess the burden of posterior segment eye diseases (PSEDs) in sub-Saharan Africa (SSA).
To assess the burden of posterior segment eye diseases (PSEDs) in sub-Saharan Africa (SSA).
We reviewed published population-based data from SSA and other relevant populations on the leading PSED, specifically glaucoma, diabetic retinopathy and age-related macular degeneration, as causes of blindness and visual impairment in adults. Data were extracted from population-based studies conducted in SSA and elsewhere where relevant.
PSEDs, when grouped or as individual diseases, are a major contributor to blindness and visual impairment in SSA. PSED, grouped together, was usually the second leading cause of blindness after cataract, ranging as a proportion of blindness from 13 to 37%.
PSEDs are likely to grow in importance as causes of visual impairment and blindness in SSA in the coming years as populations grow, age and become more urban in lifestyle. African-based cohort studies are required to help estimate present and future needs and plan services to prevent avoidable blindness.
Evaluer la charge des maladies du segment postérieur de l’œil (MSPO) en Afrique subsaharienne (ASS).
Nous avons examiné les données d’études basée sur la population, publiées pour l’ASS et d'autres populations concernées sur les principaux MSPO, en particulier le glaucome, la rétinopathie diabétique et la dégénérescence maculaire liée à l’âge, comme causes de cécité et de déficience visuelle chez les adultes. Les données ont été extraites des études de populations menées en ASS et ailleurs, le cas échéant.
Les MSPO, lorsque regroupées ou comme maladies individuelles, sont un contributeur majeur à la cécité et aux déficiences visuelles en ASS. Les MSPO, regroupées ensembles, constituaient habituellement la seconde cause de cécité après le cataracte, dans une proportion de la cécité allant de 13 à 37%.
Les MSPO sont susceptibles de croître en importance en tant que causes de déficience visuelle et de cécité en ASS dans les années à venir, avec la population qui augmente, vieillie et devient plus urbaine dans le style de vie. Des études de cohorte africaines sont nécessaires pour aider à estimer les besoins actuels et futurs et pour planifier les services de prévention de la cécité évitable.
Evaluar la carga de la enfermedad del segmento posterior del ojo (ESPO) en África Subsahariana (ASS).
Hemos revisado datos publicados de estudios poblacionales de ASS y otras poblaciones relevantes en las principales ESPO, específicamente glaucoma, retinopatía diabética y degeneración macular relacionada con la edad, como causa de ceguera y discapacidad visual en adultos. Se extrajeron datos de estudios poblacionales realizado en ASS, y en otros lugares cuando era relevante.
Las ESPO, bien agrupadas o como enfermedad individual, contribuyen de forma importante a la ceguera y a la discapacidad visual entre adultos en ASS. Las ESPO, agrupadas, eran generalmente la segunda causa de ceguera después de las cataratas, con un rango de proporción de ceguera del 13 al 37%.
Las ESPO podrían aumentar en importancia como causa de discapacidad visual y ceguera en ASS en los próximos años, a medida que las poblaciones crecen, aumentan en edad y se adopta un estilo de vida más urbano. Se requieren estudios de cohortes en África para calcular las necesidades presentes y futuras y planear servicios que eviten la ceguera prevenible.
In recent decades, there has been a marked rise in life expectancy that has contributed to a major epidemiological shift in populations worldwide (Lopez et al. 2006). These changes will increasingly lead to major public health issues in low- and middle-income countries (LMIC; Mathers & Loncar 2006). Current projections suggest that non-communicable diseases (NCDs) will contribute to two-thirds of global mortality by the year 2030 (Mathers & Loncar 2006). NCDs in LMIC have shown substantial variation in prevalence, incidence, natural history and risk factors compared with NCDs in populations in high-income countries (Boutayeb 2006).
285 million people are visually impaired (VI) worldwide, (severe visual impairment (SVI) defined as presenting visual acuity (PVA) <6/60 but ≥3/60, moderate VI defined as PVA <6/18 but ≥6/60) of whom 39 million are blind (presenting visual acuity <3/60 in the better eye; Pascolini & Mariotti 2012). Approximately 90% of those worldwide with VI live in low-income countries. NCDs are the leading causes of VI, in part due to the successful control of infectious diseases. VI is ranked sixth in the top ten causes of burden of disease in terms of disability-adjusted life-years (DALYs) in low-income, middle-income and high-income countries (Chiang et al. 2006). The sum of DALYs from VI is 66 290 000 (4.3% of total), just below HIV/AIDS at 71 460 000 (4.7%).
The number of people visually impaired in the World Health Organization (WHO) African region is estimated to be 26 million, of whom almost 6 million are blind. This is based on estimates from population-based studies in Botswana, Cameroon, Eritrea, Ethiopia, Gambia, Ghana, Kenya, Mali, Nigeria, Rwanda, Uganda and Tanzania (Pascolini & Mariotti 2012). Despite Africa having one of the highest prevalences of blindness, it is the most underserved continent in terms of human resources available to treat and manage eye disease (Resnikoff et al. 2012), with the greatest gap between existing need and provision (Bastawrous & Hennig 2012).
In 2010, the WHO reported the leading causes of visual impairment (VI) and blindness (Pascolini & Mariotti 2012). Of these, three of the nine listed leading causes are NCDs which are posterior segment in location, (i.e. affecting the back of the eye). Posterior segment eye disease (PSED) epidemiologically is commonly defined as diseases of the retina, choroid and optic nerve and primarily includes: glaucoma, age-related macular degeneration (AMD) and diabetic retinopathy (DR). These three conditions are the focus of this paper but do not constitute all PSEDs. See Figure 1.
VISION2020 is the global initiative for the elimination of avoidable blindness, launched in 1999, jointly by WHO and the International Agency for the Prevention of Blindness (IAPB) and provides technical support and advocacy to prevention of blindness activities worldwide. It aims over two decades to prevent 100 million people from becoming blind.
VISION2020 has largely focused on the elimination of anterior segment diseases, primarily cataract, as it alone causes almost half of blindness and is amenable to cure through surgery. VISION2020 has not focused on PSED to date mostly due to a lack of data on the magnitude of these conditions and lack of cost-effective treatment options. This review aims to establish the magnitude of visual impairment and blindness in SSA that can be attributed to PSED.
Our literature search was conducted for the years 1966 to September 2012 using PubMed. Keywords used included the following: posterior segment eye disease, glaucoma, age-related macular degeneration, diabetic retinopathy, correctable visual impairment, preventable, avoidable, Africa (MeSH), aphakia, blindness, visual impairment, prevalence and population.
Studies were selected for inclusion if they were population based, performed in sub-Saharan Africa with a sample size >1000, reported visual acuity impairment with its causes, had a high participation rate (>80% of the targeted sample) and presented results using the standard WHO categories of VA. WHO definitions of visual impairment are used (WHO/ICD-10 2007). We also searched reference lists of studies meeting inclusion criteria. Only published data were included.
All-cause prevalence (and 95% confidence interval [CI]) of blindness, SVI and moderate VI was extracted from each study, as well as the proportion of blindness, SVI and moderate VI due to PSED (grouped or as single diseases when available); then, the prevalence of blindness, SVI and moderate VI due to PSED was calculated from these estimates.
In total, the initial search criteria identified 112 potential manuscripts for inclusion. Review of the abstracts reduced this to 39 potential studies, of which 17 surveys, from 13 SSA countries, encompassing 88 067 individuals were included for analysis having fully met the pre-specified search criteria. Data from the following countries are presented: Burundi (Kandeke et al. 2012), Cameroon (Oye et al. 2006; Oye & Kuper 2007), Eritrea (Muller et al. 2011), Ethiopia (Berhane et al. 2007), Ghana (Budenz et al. 2012), Guinea (Moser et al. 2002), Kenya (Mathenge et al. 2007a, 2012), Malawi (Kalua et al. 2011), Nigeria (Adegbehingbe et al. 2006; Abdull et al. 2009), Rwanda (Mathenge et al. 2007b), South Sudan (Ngondi et al. 2006), Tanzania (Kikira 2007; Habiyakire et al. 2010) and Uganda (Mbulaiteye et al. 2002).
Although PSEDs are frequently collated in SSA-based epidemiological studies and presented as a single entity or group of conditions, they are clinically and pathophysiological distinct. The most common methodological approach deployed in SSA population-based studies, the rapid assessment of avoidable blindness (RAAB; Dineen et al. 2006), is not sufficiently sensitive to differentiate posterior segment causes of low vision and hence presented results are often collated.
Cross-sectional population-based studies from the last two decades performed in Africa have shown PSED to be consistently the second (and occasionally the most common) leading cause of blindness. This includes studies from Kenya (Mathenge et al. 2007a, 2012), Nigeria (Rabiu & Muhammed 2008; Abdull et al. 2009), Tanzania (Kikira 2007; Habiyakire et al. 2010), Rwanda (Mathenge et al. 2007b), Cameroon (Oye et al. 2006; Oye & Kuper 2007), Ghana (Guzek et al. 2005), Guinea (Moser et al. 2002), Burundi (Kandeke et al. 2012) and Ghana (Budenz et al. 2012; See Table 1). No longitudinal data on PSED from population-based studies in Africa have been published. A single cohort in Uganda has 3-year cumulative incidence data on visual impairment, (age-standardised incidence rate of 13.2, per 1000 PY) with AMD and glaucoma amongst the leading causes of visual loss in new cases (Mbulaiteye et al. 2003). However, no baseline clinical phenotyping data were collected in eyes initially without visual impairment, so early asymptomatic disease was not excluded.
|Country||Level||Year published||Sample size (number examined)||Response rate (%)||Age (years)||Primary cause of blindness||Secondary cause of blindness||Equipment used for diagnosis||References|
|Burundi||Provincial||2012||3684||97||≥50||Cataract (55%)||PSED (37%)||Not stated||Kandeke et al. (2012)|
|Cameroon||Limbe||2007||2215||92.3||≥40||Cataract (62%)||PSED (25%)||Direct ophthalmoscope||(Oye and Kuper (2007)|
|Cameroon||Muyuka||2006||1787||89.3||≥40||PSED (29%)||Cataract (21%)||Direct ophthalmoscope||Oye et al. (2006)|
|Eritrea||National||2011||3163||95.9||≥50||Cataract (55%)||Glaucoma (15%)||Portable slit lamp||Muller et al. (2011)|
|Ethiopia||National||2007||25650||85.4||All||Cataract (50%)||Trachoma (8%)||Direct ophthalmoscope||Berhane et al. (2007)|
|Ghana||City||2012||5603||82.3||≥40||Cataract (44%)||Glaucoma (22%)||Slit lamp/fundus camera||Budenz et al. (2012)|
|Guinea||District, Bioko||2002||3218||NS||All||Cataract (61%)||Macular Affection (21%)||Slit lamp||Moser et al. (2002)|
|Kenya||District, Nakuru (RAAB)||2007||3503||92.6||≥50||Cataract (42%)||PSED (30%)||Direct ophthalmoscope||Mathenge et al. (2007a)|
|Kenya||District, Nakuru||2012||4414||88.1||≥50||Cataract (45%)||PSED (32%)||Slit lamp/fundus camera||Mathenge et al. (2012)|
|Malawi||District||2011||3430||95.7||≥50||Cataract (48%)||Glaucoma (16%)||Direct ophthalmoscope||Kalua et al. (2011)|
|Nigeria||National||2009||13599||89.9||≥40||Cataract (43%)||Glaucoma (17%)||Slit lamp/fundus camera||Abdull et al. (2009)|
|Nigeria||Local Government Area||2008||2424||93.6%||≥50||Cataract (46%)||Surgical complications (20%)||Direct ophthalmoscope||Rabiu (2008)|
|Rwanda||Western province||2007||2206||98||≥50||Cataract (65%)||PSED (20%)||Direct ophthalmoscope||Mathenge et al. (2007b)|
|South Sudan||District||2006||2499||84.6||≥5||Cataract (41%)||Trachoma (35%)||Torch||Ngondi et al. (2006)|
|Tanzania (Kilimanjaro)||Regional||2010||3436||95.5||≥50||Cataract (51%)||PSED (36%)||Direct ophthalmoscope||Habiyakire et al. (2010)|
|Tanzania (Zanzibar)||Island||2007||3160||98.8||≥50||Cataract (67%)||PSED (25%)||Direct ophthalmoscope||Kikira (2007)|
|Uganda||15 neighbouring villages||2002||4076||98.9||≥13||Glaucoma (39%)||Cataract (23%)||Direct ophthalmoscope||Mbulaiteye et al. (2002)|
The majority of available prevalence data in Africa come from the rapid assessment of avoidable blindness (RAAB) methodology (Dineen et al. 2006). Although RAAB is a validated survey method (Mathenge et al. 2012), it has a limitation in common with more comprehensive surveys such as the Nigeria study (Dineen et al. 2008) in that detailed eye examinations are only performed in those found to have impairment of their visual acuity. As glaucoma patients usually lose central vision at the end stage of the disease, they are frequently missed unless visual field assessment is performed. Furthermore, ophthalmic assessment in RAAB relies on direct ophthalmoscopy, constraining diagnostic accuracy, so that the diseases are pragmatically grouped together as one unit.
The majority of these surveys have used the WHO coding instructions, which use the ‘principal disorder responsible for visual loss in the individual after considering disorders in either eye which are most amenable to treatment or prevention’ (World Health Organization 1988). In other words, if a patient has PSED coexistent with cataract, it will be deemed that cataract is the primary cause of blindness/VI. Therefore, most VI prevalence data available in which cataract or refractive error is the primary cause will underestimate the prevalence of PSED at all levels of visual acuity.
Current estimates suggest that there are 6.5 million people with glaucoma at all levels of vision in sub-Saharan Africa (SSA) with a projected increase to 8.4 million in 2020 (Quigley & Broman 2006). Glaucoma is estimated to be the second leading cause of blindness in Africa (Cook 2009). These estimates undertaken by Quigley and Broman (2006) are based on seven population-based studies, of which two examined individuals of African descent living outside of the African continent: in Baltimore, USA (Leske et al. 1994) and Barbados (Tielsch et al. 1991a) which has multiple limitations for inferring data. Of the five based in Africa, three were undertaken in South Africa (Salmon & Martell 1994; Rotchford & Johnson 2002; Rotchford et al. 2003), one in Ghana (Ntim-Amponsah et al. 2004) and one in Tanzania (Buhrmann et al. 2000). The studies used varying sampling methods and criteria for diagnosis of glaucoma.
No specific and sensitive test for glaucoma exists. Current reference standard diagnosis requires expensive visual field-testing equipment with expert interpretation of the optic disc and visual field findings. Standardised definitions and classifications of glaucoma in recent years have allowed for better prevalence estimates and comparisons between populations (Foster et al. 2002).
Glaucoma may be congenital or acquired and further subclassified into open-angle and closed-angle based on the mechanism by which aqueous outflow from the eye is compromised. The ‘angle’ refers to the junction between cornea and iris, which forms an angle of varying degree in each eye. Generally speaking, in glaucoma, when this angle is large and the structures within it are visible on clinical examination (gonioscopy), it is termed ‘open-angle glaucoma’ and when these structures are limited or not visible due to a narrow angle, it is termed ‘closed- or narrow-angle glaucoma’ (Kanski 2007). Primary open-angle glaucoma (POAG) disproportionately affects individuals of African descent (Quigley & Broman 2006)and is difficult to diagnose in early disease, and when diagnosis is confirmed, there is still debate on the best management in the context of limited resources and prospects for long-term follow-up (Quigley et al. 2000). Narrow-angle glaucoma prevalence is not well reported in African populations, this is in large part due to gonioscopy not being performed in the frequently used RAAB methodology and also in other more comprehensive surveys (Mathenge et al. 2012).
People of African descent (not living in Africa) have a higher prevalence of glaucoma, are more likely to develop glaucoma at an early age with more aggressive disease and have a higher risk of glaucoma related blindness than Caucasians or Asians (Mason et al. 1989; Tielsch et al. 1991b). It is therefore vital that the epidemiology of glaucoma is investigated in more detail in various populations in Africa.
Comprehensive reviews on glaucoma in Africa were published in 2009 (Cook 2009) and 2013 (Kyari et al. 2013), no new data from African population-based studies have since been published since 2009. The authors are aware of awaited data to be published from study groups in Nigeria (Dineen et al. 2008), Ghana and Kenya (Mathenge et al. 2012).
Current data on glaucoma underestimate the true prevalence, as many cases of glaucoma have preservation of central vision and do not include visual field assessment (Cook 2009). Furthermore, preferential coding of cataract due to its reversible nature often means that glaucoma is not assigned as the primary cause of blindness in a patient with visual loss from coexistent glaucoma and lens opacity, as per WHO criteria (World Health Organization 1988).
It is assumed that incidence of glaucoma in Africa will most closely reflect that of the Barbados Eye Study, whose enrolled participants were of West African descent (Leske et al. 2001, 2007). All other studies with data on glaucoma incidence have been conducted in largely Caucasian populations: the Ponza Eye Study (Cedrone et al. 2012), the Dalby Eye Study (Bengtsson 1991), the Blue Mountain Eye Study (Chandrasekaran et al. 2006), the Melbourne Visual Impairment Study (Dimitrov et al. 2003) and the Rotterdam Eye Study (de Voogd et al. 2005). Annual incidence of new glaucoma in these studies varied from 0.1 to 0.6%, the highest being in the Barbados Eye Study which was largely made up of people of African descent. To date, no data on incident glaucoma or glaucoma progression from population-based studies in Africa are available.
Diabetes is a major threat to global public health. The estimated prevalence of diabetes worldwide was 285 million in 2010, representing 6.4% of the world's adult population, with a prediction that by 2030 there will be 438 million people with diabetes (DF 2009). The most substantial increases (7 to 15 million, 111%) are expected to be in Africa and the Middle East as a result of various factors including population growth, ageing, urbanisation, dietary changes and the increase in obesity and sedentary lifestyles in these regions (King & Herman 1998).
Although no data exist from population-based studies (PBS) in Africa directly comparing ethnic variation as a risk for DR, a hospital-based study in South Africa estimated the prevalence of DR amongst patients with adult-onset diabetes attending a large community hospital to be similar in patients of African (37%), European (41%) or Indian (37%) heritage. However, ‘severe DR’ (study specific classification) was significantly more frequent in Africans (52%) and Indians (41%) than Europeans (26%; Kalk et al. 1997). The predicted rise in proportion of adults suffering from diabetes will inevitably lead to an increase in the prevalence of DR (Williams et al. 2004).
The detection of DR in Africa remains a challenge in part due to a lack of necessary equipment and skilled manpower (Rotimi et al. 2003). The authors of this review [also cited in reference: (Burgess et al. 2013)] identified two high-quality, population-based, cross-sectional studies reporting DR prevalence in Africa (but not SSA). The Diabetes in Egypt project (1993; Herman et al. 1998) reported the proportion of DR and PDR in individuals with diabetes to be 31.6% and 0.9%, respectively. The Mauritius diabetes complication study (Dowse et al. 1998) reported 30.2% DR and 1.3% PDR; the prevalence of PDR in subjects with known diabetes was 2.3%. These figures are comparable with prevalence estimates reported in recent American and European studies.
Egypt and Mauritius are ethnically and demographically very different to most countries of sub-Saharan Africa; the findings of these studies should be generalised to other settings with caution.
There are also estimates of the prevalence of DR amongst diabetics from high-quality clinic-based studies in Africa. Very high prevalences of DR, PDR and maculopathy have been reported. A study from Malawi reported 32.0% DR, 5.7% PDR, 15% sight-threatening maculopathy (Glover et al. 2012). Two separate studies from South Africa have found comparable results: Mash et al. found 62.4% DR, 6.1% PDR and 15.2% with any maculopathy (Mash et al. 2007); Rotchford et al. found DR 40.3%, PDR 5.6%, 10.3% CSME (Rotchford 2002).
Evidence from unpublished data supports urbanisation as a risk factor for DR. Slit-lamp assessment of the retina assessing DR in a South-African PBS (Rotchford & Johnson 2002; Rotchford et al. 2003) demonstrated a 0.7% prevalence of DR (NPDR 0.6%, PDR 0.1%) in rural communities and a 2.1% prevalence of DR (NPDR 1.8%, PDR 0.3%) in urban communities (A. Rotchford, unpublished data).
Estimates of the proportion of African patients with diabetes who are visually impaired are high even compared with older European and American studies. The population-based Nigerian national blindness and visual impairment survey was conducted between 2005 and 2007 (Abdull et al. 2009). DR was identified as the primary cause of visual impairment in 0.29% of 3129 subjects with uncorrected VA worse than 6/12 and in 0.5% of those with acuity less than 3/60. This study is likely to underestimate the visual impact of DR as examiners were instructed to preferentially record treatable, rather than preventable, causes of visual impairment.
No population-based cohort study was identified providing incidence data on DR in SSA. However, two cohort studies of DR in Africa were identified by this review, one of which was in SSA. A survey of diabetes complications in Mauritius was followed up 6 years later (Dowse et al. 1998). Of subjects with diabetes in the initial survey 40.5% were re-examined for DR (Tapp et al. 2006). Six-year incidence of DR was 23.8%. Duration of diabetes and fasting blood glucose were independently associated with incidence of retinopathy. Six-year progression to PDR was reported from no DR (0.4%), mild NPDR (5.2%) and moderate NPDR (29.4%).
In South Africa, a cohort of patients with insulin-dependent diabetes mellitus (IDDM) diagnosed before age 30 years was followed up over time (Gill et al. 1984). In those subjects seen after 10 years of follow-up, prevalence of DR had increased from 6% to 52% and PDR from 0 to 3% (Gill et al. 1995). In subjects seen at 20 years, prevalence of DR had increased from 12% to 59%. No incidence data were collected (Gill et al. 2005).
No other prospective cohort studies were identified. However, a study reflecting cumulative incidence of DR from South Africa (Distiller et al. 2010) reported on 1520 type 1 and 8026 t ype 2 patients who had maintained membership for ≥5 years in a community-based, privately funded diabetes management programme. In type 1 participants, the prevalence of any retinopathy at baseline and at 5 years was 22.3% and 28.0%, respectively, and in type 2 participants 20.5% and 26.6%, respectively.
The majority of data globally on AMD are from Caucasians and Asian populations (Vingerling et al. 1996; Cruickshanks et al. 2001; Buch 2005; Buch et al. 2005; Munoz et al. 2005; Arnarsson et al. 2006; Chen et al. 2008; Yasuda et al. 2009; Choudhury et al. 2011) with a paucity of data from peoples of African descent. Data on Africans are largely from studies undertaken in African populations living outside of the African continent (Leske et al. 2004, 2007). Comparative data between Caucasians and Africans living in the same geographical area have suggested differing predispositions towards AMD (Sommer et al. 1991). A single population-based study based in SSA (Kenya) determining the prevalence of AMD was identified (Mathenge et al. 2013). Early and late AMD prevalence in adults aged 50 years and above was 11.2% and 1.2%, respectively, amongst participants graded on digital retinal images (n = 3,304). After controlling for age, women had a higher prevalence of early AMD than men (odds ratio 1.5; 95% CI, 1.2–1.9), and the overall prevalence rose significantly with each decade of age (Mathenge et al. 2013).
The incidence of AMD has been reported in population-based studies in the Americas, Australasia, Europe, and Asia; however, no data exist from the African continent to date. With the exceptions of the Latino Eye Study (Varma et al. 2010) and the Barbados Eye Study (Leske et al. 2004, 2006), all data are in Caucasian populations, and inferred data from the Barbados study suggest incident early AMD is similar to elsewhere in the world, but late AMD is less common, possibly suggesting a protective mechanism.
We found through our review of the literature that PSEDs are an important cause of vision loss in SSA countries. Selection bias may have led to information from French- and Portuguese-speaking countries being omitted; data from Egypt and Mauritius are unlikely to be representative for the SSA, and data not in the peer-reviewed literature were also omitted and may have been a source of bias.
The detection of and treatment for PSED poses many challenges to countries that currently lack the necessary infrastructure and resources. VISION 2020 has placed priority on conditions deemed more straightforward to treat, and this strategy has proven largely successful.
PSEDs differ from the leading anterior segment eye diseases (cataract and refractive error) in prevention/treatment, as no cures currently exist (with the exception of angle closure glaucoma). Surgical intervention can restore vision in those visually impaired from cataract, and provision of glasses can restore or improve vision in people with refractive error. However, established visual loss from PSED is difficult to reverse, and for most conditions, there is no ‘curative’ treatment.
Medical and/or surgical intervention for glaucoma can slow disease progression and thereby reduce the risk of further sight loss (Heijl et al. 2002). Systemic control of diabetes mellitus, retinal laser treatment, intravitreal injections and vitreoretinal surgery in sight-threatening DR can stabilise and, to some degree, improve DR status and thereby also prevent sight loss (1993). Currently no cure for AMD exists, although intravitreal therapy is available for end-stage wet AMD (approximately 10% of all AMD cases). The infrastructure required to detect AMD and deliver treatment as well as the cost of treatment itself is currently prohibitively expensive for use in most LMIC settings but is widely used in high-income countries (Bowler et al. 2012). Vitamin supplementation has shown some evidence of risk reduction in progression of subtypes of AMD (Evans 2006), but not prevention of AMD (Evans & Lawrenson 2012) and again may be prohibitively expensive.
This review suggests that PSEDs account for a large proportion of people with vision loss living in SSA. In recent years, improved methodologies and understanding may account for some increase in estimates of prevalence. In particular, the affordable RAAB methodology (Dineen et al. 2006) has led to increased numbers of researchers undertaking population-based surveys in SSA.
The majority of existing data on NCDs, including PSED, from LMIC are from cross-sectional studies providing valuable data on prevalence and risk factors. Longitudinal studies provide the opportunity to investigate the natural history of diseases, which is necessary in developing health policies at local and national levels. Few longitudinal cohort studies from LMIC have been conducted due to barriers including expense, complex logistical planning and political challenges.
A change in the focus of programme managers and policymakers over the coming decades is required if the prevalence and incidence of PSED in SSA increases as predicted. This increase is likely with extended life expectancies and success of the VISION 2020 in the treatment for anterior segment eye diseases and infectious diseases of the eye. Urbanisation and westernised lifestyles may also play a role in diseases such as diabetes and consequently DR.
Many studies worldwide have collected cross -sectional survey data on PSED prevalence; however, few studies have data on incident PSED with no SSA-based eye disease cohort studies to date. The best estimates of incidence for Africa are therefore extrapolated from studies conducted elsewhere in the world. Furthermore, investigating PSED in Africa offers a new perspective on account of the different exposures and genetic make-up of these populations compared with those studied thus far, which may reveal new insights into the cause and natural history of these diseases.
Inferring data from high-income countries undermines efforts to establish studies in LMIC, which will guide the effective use of minimal existing resources to deal with the growing burden of NCDs.
Large, community-based cross-sectional and cohort studies are needed to estimate prevalence of disease, risk factors for disease, as well as incidence and progression across Africa. Evidence for effectiveness and economics of screening of and treatment for PSED in low resource settings is vital for health service planners.